Jazz Pharmaceuticals JAZZ Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's current debt?
- Jazz Pharmaceuticals (JAZZ) reported current debt of $1.03B in Q1 2026.
- How has Jazz Pharmaceuticals's current debt changed year-over-year?
- Jazz Pharmaceuticals's current debt increased by 3224.2% year-over-year, from $31M to $1.03B.
- What is the long-term trend for Jazz Pharmaceuticals's current debt?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's current debt has grown at a 33.1% compound annual growth rate (CAGR), from $246.32M to $1.03B.
- What does current debt mean?
- The amount of long-term debt that must be paid within one year.
- How do you interpret current debt?
- An increase indicates higher near-term cash requirements for debt repayment, potentially impacting liquidity ratios.
- How does current debt compare across companies?
- Monitored closely by credit analysts to assess refinancing risk compared to peer debt maturity profiles.